Novel leuconostoc mesenteroides strain
By providing Leuconostoc mesenteroides strains CJRS-10671 and CJRS-10672 with high enzyme activity, the problem of insufficient anti-cancer and immune-enhancing effects in existing technologies has been solved, achieving anti-cancer effects and immune-enhancing effects in food and feed.
Patent Information
- Application Number
- CN202280089009.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2021-11-17
- Filing Date
- 2022-11-17
- Publication Date
- 2024-11-15
AI Technical Summary
There is a lack of effective anti-cancer and immune-enhancing lactic acid bacteria in the current technology, especially in fermented foods where the potential of Leuconostoc mesenteroides is not fully utilized.
The strains of Leuconostoc mesenteroides CJRS-10671 and CJRS-10672 are provided, which have high enzyme activity and immune-enhancing effects. They increase the secretion of immune-enhancing cytokines IL-6, IL-12p70 and IFNγ by enhancing the efficacy of CD8 T cells. They can be used in food and feed, and in combination with anticancer agents for cancer treatment.
It exhibits significant anti-cancer effects, effectively enhancing immune function and inhibiting cancer cell growth by inhibiting cancer cell cycle and strengthening immune response in food and feed.
Smart Images

Figure CN118974239A_ABST
Abstract
Description
Technical Field
[0001] The present disclosure relates to novel strains of Leuconostoc mesenteroides. Background Art
[0002] Lactic acid bacteria are microorganisms that are an important part of the microbial industry. General foods fermented by lactic acid bacteria include kimchi, yogurt, cheese, buttermilk, sauerkraut, etc., and lactic acid fermentation by lactic acid bacteria is also used for the ripening and preservation of unheated sausages.
[0003] In particular, various lactic acid bacteria including Leuconostoc mesenteroides have been found in kimchi, a traditional fermented food.
[0004] In addition, it has been reported that lactic acid bacteria exhibit various health-promoting effects, such as intestinal regulation, inhibition of harmful bacteria, immune regulation, blood cholesterol reduction, anti-cancer effects, etc. (WO2022-103138A1). Summary of the invention
[0005] [Technical issues]
[0006] The present disclosure provides strains of Leuconostoc mesenteroides.
[0007] [Technical solution]
[0008] One aspect of the present disclosure provides a Leuconostoc mesenteroides CJRS-10671 (Accession No.: KCCM13059P) strain.
[0009] Another aspect of the present disclosure provides a Leuconostoc mesenteroides CJRS-10672 (Deposit No.: KCCM13060P) strain.
[0010] [Beneficial Effects]
[0011] The novel Leuconostoc mesenteroides strain according to the present disclosure exhibits anticancer effects, and exhibits immune enhancing effects, such as increasing the secretion of immune enhancing cytokines IL-6, IL-12p70, and IFNγ by enhancing CD8 T cell potency, and thus can be effectively used in food or feed. BRIEF DESCRIPTION OF THE DRAWINGS
[0012] Figure 1 The enzyme activities of Leuconostoc mesenteroides strains CJRS-10671 and CJRS-10672 are exemplified.
[0013] Figure 2 The hemolytic activity of strains CJRS-10671 and CJRS-10672 is exemplified.
[0014] Figure 3The intestinal adherence of strains CJRS-10671 and CJRS-10672 is illustrated.
[0015] Figure 4 Interleukin (IL)-6 secretion by CJRS-10671 and CJRS-10672 strains in a macrophage cell line is exemplified.
[0016] Figure 5 IL-12p70 secretion by CJRS-10671 and CJRS-10672 strains in human peripheral blood mononuclear cells (PBMCs) is exemplified.
[0017] Figure 6 The interferon-γ (IFNγ) secretion capacity of CD8 T cells caused by CJRS-10671 and CJRS-10672 strains in mouse splenocytes and human PBMCs is illustrated.
[0018] Figure 7 The cell cycle arrest effect of CJRS-10671 and CJRS-10672 strains on cancer cells is exemplified.
[0019] Figure 8 The expression of cyclin B1 and cyclin-dependent kinase 1 (CDK1), which are factors associated with cell cycle arrest in cancer cells, by the CJRS-10671 and CJRS-10672 strains is exemplified.
[0020] Fig. 9 Cancer cell death caused by CJRS-10671 and CJRS-10672 strains is exemplified.
[0021] Fig.10 The tumor suppressive effect caused by administration of CJRS-10671 and CJRS-10672 in a mouse lung cancer model (LLC1) is exemplified.
[0022] Fig.11 The IFNγ secretion capacity of CD8 T cells induced by administration of CJRS-10671 in a mouse lung cancer model (LLC1) is exemplified.
[0023] Fig.12 The IFNγ secretion capacity of CD8 T cells induced by administration of CJRS-10672 in a mouse lung cancer model (LLC1) is exemplified.
[0024] Fig.13 The IFNγ secretion capacity of CD8 T cells in tumor tissues caused by administration of CJRS-10671 and CJRS-10672 in a mouse lung cancer model (LLC1) is exemplified.
[0025] Fig.14 The changes in myeloid-derived suppressor cells (MDSCs), which are immunosuppressive cells, caused by the administration of CJRS-10671 and CJRS-10672 in a mouse lung cancer model (LLC1) are exemplified.
[0026] Fig.15 Profiling of immune cell changes caused by administration of CJRS-10671 in a mouse lung cancer model (LLC1) is exemplified.
[0027] Fig.16 Analysis of immune cell changes caused by administration of CJRS-10672 in a mouse lung cancer model (LLC1) is exemplified. DETAILED DESCRIPTION
[0028] The present disclosure will be specifically described as follows. Each description and embodiment in the present disclosure may also be applied to other descriptions and embodiments. That is to say, all combinations of various elements in the present disclosure fall within the scope of the present disclosure. In addition, the scope of the present disclosure is not limited by the following specific description. In addition, those skilled in the art will recognize or be able to use no more than routine experiments to determine many equivalents to the specific embodiments of the disclosure described herein. In addition, these equivalents should be intended to fall within the scope of the present disclosure.
[0029] According to one aspect of the present disclosure, a Leuconostoc mesenteroides CJRS-10671 (Accession No.: KCCM13059P) strain is provided.
[0030] According to another aspect of the present disclosure, a Leuconostoc mesenteroides CJRS-10672 (Deposit No.: KCCM13060P) strain is provided.
[0031] As used herein, the term "Leuconostoc mesenteroides" refers to a lactic acid bacterium having a spherical shape, and is a probiotic or lactic acid bacterium known to have a function of fermenting foods such as kimchi.
[0032] The Leuconostoc mesenteroides strain of the present disclosure may be at least one selected from CJRS-10671 deposited under the accession number KCCM13059P or CJRS-10672 deposited under the accession number KCCM13060P.
[0033] The CJRS-10671 strain of the present disclosure may have high enzyme activities of β-galactosidase, α-glucosidase, and β-glucosidase, and the CJRS-10672 strain of the present disclosure may have enzyme activity of β-glucosidase.
[0034] In addition, the strains disclosed herein may have intestinal regulating effects and immune enhancing effects.
[0035] According to still another aspect of the present disclosure, a composition is provided, which contains CJRS-10671 deposited with the accession number KCCM13059P or CJRS-10672 deposited with the accession number KCCM13060P; a culture of the KCCM13059P or KCCM13060P strain; or a substance derived from the KCCM13059P or KCCM13060P strain.
[0036] The composition of the present disclosure may be a food or a feed.
[0037] The bacterial strain disclosed herein can exist in the form of living cells or dead cells, and can exist in the form of drying or freeze-drying. The culture disclosed herein may include living cell cultures (i.e., products obtained by culturing living cells in a culture medium), cultures obtained by killing living cells in living cell cultures or culture filtrates (i.e., products obtained by removing dead cells or living cells from the culture). The components derived from the bacterial strain disclosed herein may include cytoplasmic fractions obtained by cell destruction and containing extracellular vesicles (EV) and the like. In addition, the form of lactic acid bacteria suitable for being included in the pharmaceutical composition, its preparation method, separation methods of bacterial strain-derived components, etc. are well known to those skilled in the art.
[0038] Specifically, the strain of the present disclosure may be a strain obtained by inoculating to 0.1% to 10% in an MRS liquid medium and culturing at 25° C. to 40° C. for 4 to 72 hours.
[0039] The strains disclosed herein may have anti-cancer, anti-inflammatory and immune-enhancing effects.
[0040] In the present disclosure, cancer may include any type of cancer known in the art, but is not limited thereto, and examples thereof may include lung cancer (e.g., non-small cell lung cancer, small cell lung cancer, malignant mesothelioma), mesothelioma, pancreatic cancer (e.g., pancreatic duct cancer, pancreatic endocrine tumor), pharyngeal cancer, laryngeal cancer, esophageal cancer, gastric cancer (e.g., papillary adenocarcinoma, mucinous adenocarcinoma, adenosquamous carcinoma), duodenal cancer, small intestine cancer, colorectal cancer (e.g., colon cancer, rectal cancer, anal cancer, familial colorectal cancer, hereditary non-polyposis colorectal cancer, gastrointestinal stromal tumor), breast cancer (e.g., invasive ductal carcinoma, non-invasive ductal carcinoma, inflammatory breast cancer), ovarian cancer (e.g., ovarian epithelial carcinoma, extragonadal germ cell tumor, ovarian germ cell tumor, ovarian low malignant potential tumor tumor), testicular tumors, prostate cancer (e.g., hormone-dependent prostate cancer, hormone-independent prostate cancer), liver cancer (e.g., hepatocellular carcinoma, primary liver cancer, extrahepatic bile duct cancer), thyroid cancer (e.g., medullary thyroid carcinoma), kidney cancer (e.g., renal cell carcinoma, transitional cell carcinoma of the renal pelvis and ureter), uterine cancer (e.g., cervical cancer, cancer of the uterine body, uterine sarcoma), brain tumors (e.g., medulloblastoma, glioma, pineal astrocytoma, pilocytic astrocytoma, diffuse astrocytoma, anaplastic astrocytoma, and pituitary adenoma), retinoblastoma, skin cancer (e.g., basal cell tumor, malignant melanoma), sarcoma (e.g., rhabdomyosarcoma, leiomyosarcoma, soft tissue sarcoma), malignant bone tumors, bladder cancer, blood cancer (e.g., multiple myeloma, leukemia, malignant lymphoma, Hodgkin's disease disease), chronic myeloproliferative disease), cancer of unknown primary focus, etc., but not limited thereto, specifically, it can be lung cancer or colorectal cancer.
[0041] The strain or composition disclosed herein can exhibit anti-cancer effects. Specifically, the anti-cancer effect may include cancer cell killing or tumor growth inhibition effects (Example 9 and Example 10-1).
[0042] For example, the strain or composition of the present disclosure can inhibit the cell cycle of cancer cells to show cancer cell killing or tumor growth inhibition, thereby resulting in an anti-cancer effect (Example 8).
[0043] As another example, the strain or composition of the present disclosure can exhibit anti-inflammatory or immune-enhancing effects by increasing the secretion of IL-6, IL-12p70, and interferon gamma (IFNγ), which are immune-enhancing cytokines (Example 7).
[0044] In the present disclosure, the strain or composition of the present disclosure can be administered in combination with an anticancer agent. Examples of anticancer agents may include anticancer agents based on taxanes, statins, alkylating agents, platinum-based drugs, antimetabolites, antibiotics, anticancer agents based on vinca alkaloids, targeted therapeutic agents, anticancer immunotherapeutics, cancer vaccines, cell therapy agents, oncolytic viruses and combinations thereof, but are not limited thereto, and specifically, the anticancer agent may be an anticancer immunotherapeutic agent.
[0045] Examples of the taxane-based anticancer agent may be paclitaxel, docetaxel, larotaxel, cabazitaxel, etc., but are not limited thereto.
[0046] Examples of statins may include simvastatin, atorvastatin, lovastatin, fluvastatin, cerivastatin, pitavastatin, etc., but are not limited thereto.
[0047] Examples of the alkylating agent may be nitrogen mustard-based drugs, ethyleneimine-based and methylmelamine-based drugs, methylhydrazine derivatives, alkylsulfonate-based drugs, nitrosourea-based drugs, triazine-based drugs, etc., but are not limited thereto.
[0048] Examples of the platinum-based drug may be cisplatin, carboplatin, oxaliplatin, etc., but are not limited thereto.
[0049] Examples of antimetabolites may be folate antagonist-based drugs, purine antagonist-based drugs, pyrimidine antagonist-based drugs, etc., but are not limited thereto.
[0050] Examples of the antibiotics may be etoposide, topotecan, irinotecan, idarubicin, epirubicin, dactinomycin, doxorubicin, adriamycin, daunorubicin, bleomycin, mitomycin C, mitoxantrone, etc., but are not limited thereto.
[0051] Examples of the vinca alkaloid-based anticancer drugs may include vincristine, vinblastine, vinorelbine, etc., but are not limited thereto.
[0052] Examples of targeted therapeutic agents may be epidermal growth factor receptor (EGFR) targeted therapeutic agents, human epidermal growth factor receptor 2 (HER2) targeted therapeutic agents, CD20 (B cell marker) targeted therapeutic agents, CD33 (myeloid cell surface antigen) targeted therapeutic agents, CD52 (cluster of differentiation 52) targeted therapeutic agents, CD30 (tumor necrosis factor receptor superfamily member 8) targeted therapeutic agents, breakpoint cluster region protein tyrosine protein kinase (bcr-abl) / tyrosine kinase receptor (c-Kit) targeted therapeutic agents, anaplastic lymphoma receptor tyrosine kinase (ALK) targeted therapeutic agents, anti-angiogenesis targeted therapeutic agents, mammalian target of rapamycin (mTOR) targeted therapeutic agents, cyclin-dependent kinase 4 / 6 (CDK4 / 6) targeted therapeutic agents, poly (ADP-ribose) polymerase (PARP) targeted therapeutic agents, proteasome inhibitors, tyrosine kinase antagonists, protein kinase C inhibitors, farnesyl transferase inhibitors, etc., but are not limited thereto.
[0053] Examples of anti-cancer immunotherapeutic agents may be anti-programmed cell death protein 1 (anti-PD-1), anti-programmed cell death ligand 1 (anti-PD-L1), cytotoxic T lymphocyte-associated antigen 4 (CTLA4), CTLA4 / B7-1 / B7-2 interaction inhibitor, cluster of differentiation 47 / signal regulatory protein (CD47 / SIRP) interaction inhibitor, anti-T cell immunoglobulin and mucin domain 3 (anti-Tim3), anti-lymphocyte activation gene 3 (anti-LAG3), etc., but are not limited thereto.
[0054] Specifically, the anti-cancer agent of the present disclosure may be, but is not limited to, an anti-PD-1 immunotherapeutic agent.
[0055] In the present disclosure, co-administration may be simultaneous, sequential or reverse sequential administration of the strain or composition and the anticancer agent, but the order of administration is not limited and falls within the scope of the present disclosure, as long as the two are administered at an administration interval that can exhibit the pharmacological effects of both. The strain or composition and the anticancer agent may be prepared into a preparation separately, or may be prepared into a formation, but is not limited thereto.
[0056] In the present disclosure, the administration of the strain or composition of the present disclosure can be combined with anticancer therapy. Examples of anticancer therapy can be radiotherapy, neoadjuvant therapy, chemotherapy, targeted therapy, photodynamic therapy, etc., but are not limited thereto, and can include all types of anticancer therapies known in the art.
[0057] The food composition of the present disclosure may be in the form of a food additive.
[0058] The food composition may further contain food additives, unless otherwise specified, whose suitability as a "food additive" is determined according to the standards and guidelines for the corresponding items in the General Rules and General Test Methods of the Food Additive Code approved by the Ministry of Food and Drug Safety.
[0059] Items listed on the Food Additives Codex may include, for example: chemically synthesized products such as ketones, glycine, potassium citrate, niacin and cinnamic acid; natural additives such as persimmon pigment, licorice root extract, crystalline cellulose and guar gum; and mixed preparations such as sodium L-glutamate preparations, alkaline agents for addition to noodles, preservative preparations and tar color preparations.
[0060] Examples of foods containing the active ingredient of the present invention may include: confectionery, such as bread, rice cakes, dry snacks, candy, chocolate, chewing gum, and jam; ice cream products, such as ice cream, frozen desserts, and ice cream powder; dairy products, such as milk, low-fat milk, lactose-degraded milk, processed milk, goat milk, fermented milk, butter milk, condensed milk, milk cream, and so on. cream), natural cheese, processed cheese, milk powder and whey; meat products, such as processed meat products, processed egg products and hamburgers; fish products, such as fish cakes and processed fish products, such as ham, sausage and bacon; noodles, such as ramen, dried noodles, fresh noodles, instant fried noodles, gelatinized dried noodles, modified cooked noodles, frozen noodles and pasta; beverages, such as fruit drinks, vegetable drinks, carbonated drinks, soy milk, lactobacillus drinks (including yogurt) and mixed drinks; seasoning foods, such as soy sauce, fermented bean paste, red pepper sauce, black bean sauce, quickly fermented bean paste, mixed sauce, vinegar, sauce, ketchup, curry and condiments; and fermented foods, but not limited to them.
[0061] In addition, the food composition of the present disclosure may also contain various nutrients, vitamins, electrolytes, flavoring agents, coloring agents, pectin acid and its salts, alginic acid and its salts, organic acids, protective colloid thickeners, pH regulators, stabilizers, preservatives, glycerol, alcohols, carbonating agents used in carbonated beverages, etc. In addition, the food composition of the present disclosure may contain pulp used to make natural fruit juices, fruit juice drinks and vegetable drinks. These ingredients can be used alone or in combination.
[0062] In addition to the feed composition, the feed composition may be in the form of a feed additive composition.
[0063] When the composition is manufactured as a feed additive, the composition can be manufactured as a high concentration solution of 20% to 90% or in the form of a powder or granules. The feed additive may further contain any one or more of the following: organic acids, such as citric acid, fumaric acid, adipic acid, lactic acid and malic acid; phosphates, such as sodium phosphate, potassium phosphate, acid pyrophosphate and polyphosphate; or natural antioxidants, such as polyphenols, catechins, α-tocopherol, rosemary extract, vitamin C, green tea extract, licorice extract, chitosan, tannic acid and phytic acid. When the composition is produced as a feed, the composition can be formulated in a common feed form and can contain common feed ingredients together.
[0064] Feed and feed additives may further include: cereals, such as powdered or crushed wheat, oats, barley, corn and rice; plant protein feeds, such as feeds with rapeseed, soybeans and sunflower as main ingredients; animal protein feeds, such as blood meal, meat meal, bone meal and fish meal; and sugar and dairy products, such as dry ingredients including various types of milk powder and whey powder, and in addition to the above, may further contain nutritional supplements, digestion and absorption promoters, growth promoters, etc.
[0065] Feed additives can be administered to animals alone or in combination with other feed additives in edible carriers. Feed additives can be easily administered to animals as top dressing (top dressing) by directly mixing with animal feed, or as an oral preparation separated from feed. When feed additives are administered separately from animal feed, feed additives can be prepared as immediate release or sustained release preparations, combined with pharmaceutically acceptable edible carriers well known in the art. Edible carriers can be solid or liquid, such as corn starch, lactose, sucrose, bean slices, peanut oil, olive oil, sesame oil and propylene glycol. When using solid carriers, feed additives can be in the form of tablets, capsules, powders, lozenges, lozenges or non-dispersed top dressing. When using liquid carriers, feed additives can be preparations of gelatin soft capsules, syrups, suspensions, emulsions or solutions.
[0066] Feed and feed additives may contain adjuvants such as preservatives, stabilizers, humectants, emulsifiers and solution enhancers. Feed additives can be used by soaking, spraying or mixing into animal feed.
[0067] The feed or feed additive of the present disclosure can be applied to feeds of many animals including mammals, poultry and fish.
[0068] The feed or feed additive of the present disclosure can be used for: mammals, such as pigs, cattle, horses, sheep, rabbits, goats, rodents and experimental rodents (including rats, hamsters and guinea pigs), and pets (such as dogs and cats); poultry, such as chickens, turkeys, ducks, geese, pheasants and quail; and fish, such as carp, crucian carp and trout, but are not limited thereto.
[0069] According to yet another aspect of the present disclosure, provided is a method for preventing or treating cancer, the method comprising administering the strain or composition of the present disclosure to a subject.
[0070] The strain or composition of the present disclosure may be provided as a pharmaceutical composition for preventing or treating cancer, and the strain, composition and cancer are as described above.
[0071] The treatment method disclosed herein includes administering a pharmaceutically effective amount of the strain or composition of the present disclosure to a subject suspected of having cancer. Subjects may refer to any mammal, including dogs, cattle, horses, rabbits, mice, rats, chickens and humans, but mammals disclosed herein are not limited to these examples. The strain or composition may be administered via parenteral, subcutaneous, intraperitoneal, intrapulmonary and intranasal routes. For local treatment, if necessary, the strain or composition may be administered by appropriate methods, including intralesional administration. Parenteral injections include intramuscular, intravenous, intraarterial, intraperitoneal or subcutaneous administration. Preferred preparations are intravenous, subcutaneous, intradermal, intramuscular or instilled preparations. The preferred dosage of the strain or composition disclosed herein may vary according to the subject's condition and body weight, severity of the disease, drug type, and route of administration and time, and may be appropriately determined by those skilled in the art.
[0072] Example
[0073] Hereinafter, the present invention will be described in detail with reference to Examples. However, these embodiments are only preferred embodiments for illustrating the present disclosure, and are therefore not intended to limit the scope of the present disclosure. Meanwhile, the technical matters described herein can be fully understood and easily implemented by researchers in the technical field of the present disclosure or similar technical fields. In addition, throughout the specification, many papers and patent documents are cited, and their citations are provided. The disclosures of the cited documents and patent documents are incorporated into this specification by reference as a whole, and the level of the technical field to which the present disclosure falls and the details of the present disclosure are more clearly explained.
[0074] Example 1: Sugar fermentation characteristics of Leuconostoc mesenteroides strains
[0075] The intestinal membrane Leuconostoc strains CJRS-10671 and CJRS-10672 isolated from Korean kimchi were cultured using MRS liquid medium and agar medium from Difco, respectively. Various culture media were prepared according to the experimental protocol and then sterilized at 121°C for 15 minutes. Two days before the experiment, the stock solution of each strain was inoculated in MRS liquid medium at 1%, and statically cultured at 37°C for 20 hours, and then inoculated again in MRS liquid medium at 2% (activated), and cultured at 27°C for 20 hours.
[0076] The sugar fermentation characteristics of CJRS-10671 and CJRS-10672 strains cultured in this way for 49 carbohydrates were detected using the API 50CHL kit (Biomerieux, France). Specifically, the strains that were subcultured for two generations were rinsed with phosphate buffered saline (PBS), and then each strain was suspended in API 50CHL medium that met McFarland standard 2.0, inoculated on the strip, and then cultured at 37°C for 24 hours. The yellow color caused by the use of carbohydrates was read as indicating a positive reaction, while the purple color caused by the non-use of carbohydrates was read as indicating a negative reaction.
[0077] Table 1
[0078]
[0079]
[0080] Example 2: Enzyme activity of strains
[0081] In order to analyze the biochemical characteristics of the CJRS-10671 and CJRS-10672 strains of Example 1, 19 enzyme activities of the strains were detected using the API ZYM kit (Biomerieux, France).
[0082] The results are shown in Table 2 and Figure 1 As shown in , it was confirmed that CJRS-10671 showed high enzyme activity in β-galactosidase, α-glucosidase, and β-glucosidase, and CJRS-10672 showed high enzyme activity in β-glucosidase.
[0083] Table 2
[0084]
[0085]
[0086] Example 3: Hemolytic activity of strains
[0087] To determine whether the CJRS-10671 and CJRS-10672 strains of Example 1 have hemolytic activity, the strains were plated on blood agar supplemented with 5% defibrinated sheep blood (MB cells, Korea) and cultured at 37°C for 24 hours, and then observed whether clear areas were formed around the colonies.
[0088] Results, such as Figure 2 As shown in , no clear zone resulting from the lysis of hemocytes was observed around the colonies, indicating that the CJRS-10671 and CJRS-10672 strains had no hemolytic activity.
[0089] Example 4: Antibiotic resistance of strains
[0090] In order to determine the antibiotic resistance of the CJRS-10671 and CJRS-10672 strains of Example 1, an antibiotic resistance test was performed to determine the minimum inhibitory concentration (MIC) according to the EFSA antibiotic resistance testing guidelines. The guidelines set standards for the critical values (cut-off values) of 8 antibiotics for Leuconostoc mesenteroides.
[0091] The results of the MIC test showed that strains CJRS-10671 and CJRS-10672 met the criteria for 5 antibiotics, but exceeded the MIC criteria for some antibiotics, so a genetic analysis was performed according to the EFSA guidelines to determine whether the antibiotic resistance was intrinsic or acquired. The results are shown in Table 3 below. According to the EFSA guidelines, strains with intrinsic resistance can be used because it is unlikely that antibiotic resistance genes can be transferred from the outside to other bacteria. Strains of the genus Leuconostoc have been reported to be resistant to chloramphenicol (MICs ≥ 4 μg / mL), but it is known that these resistances may be intrinsic to the genus Leuconostoc and are unlikely to be caused by horizontal gene transfer to other bacteria (AB Florez, 2005).
[0092] Table 3
[0093]
[0094] Example 5: Acid tolerance and bile salt tolerance of strains
[0095] Since it is important for oral preparations to stably reach the intestines and exert their efficacy, the acid tolerance and bile salt tolerance of the strain were evaluated to determine its suitability as an oral preparation. Specifically, an acid tolerance test was performed in which the strain subcultured for two generations was inoculated at 1% in a PBS solution adjusted to pH 3.0 with 1N HCl and cultured at 37°C for 2 hours, and then a comparison was made between the initial viable cell count and the viable cell count after culture.
[0096] Bile salt tolerance was determined, wherein the activated strain was inoculated at 1% in a PBS solution containing 1% ox bile (Difco, USA) and cultured at 37°C for 2 hours, and then a comparison was made between the initial viable cell count and the viable cell count after the culture.
[0097] As a result, as shown in Table 4 below, based on 100% initial viable cell count, the CJRS-10671 strain showed 95.7% acid tolerance and 136.6% bile salt tolerance, and based on 100% initial viable cell count, the CJRS-10672 strain showed 120.6% acid tolerance and 67.9% bile salt tolerance.
[0098] Table 4
[0099] bacteria Acid resistance (%) Bile salt tolerance (%) CJRS-10671 95.7±12.2 136.6±24.6 CJRS-10672 120.6±31.1 67.9±3.3
[0100] Example 6: Intestinal Adhesion of Strain
[0101] In order to determine the stability and adaptability of the CJRS-10671 and CJRS-10672 strains of Example 1 in the intestinal experimental environment, the intestinal adhesion of the strains was evaluated using the HT-29 cell line (Korean Cell Line Bank, KCLB; Seoul, South Korea) as the intestinal epithelial cells. Specifically, the HT-29 cell line was cultured in Dulbecco's modified Eagle's minimal essential medium (DMEM) supplemented with 10% fetal bovine serum (FBS, Gibco, Carlsbad, CA, USA), 100 U / mL penicillin and 0.1 mg / mL streptomycin at 37°C and 5% CO2 atmosphere. 5 HT-29 cell line was seeded in cells / 24 wells to form a monolayer of about 80%, and then washed twice with PBS to remove the antibiotics contained in DMEM. The strains subcultured for two generations were washed with PBS and then dissolved in DMEM without antibiotics and cultured at 2×10 7The ratio of CFU / well was processed. After culturing for 2 hours at 37°C and 5% CO2, non-adherent cells were removed by washing 3 times with PBS, and only adherent HT-29 cells and strain cells were separated by adding trypsin ethylenediaminetetraacetic acid (EDTA), and then the living cells were counted with MRS agar. The degree of intestinal adhesion was expressed as the number of CFU of adherent strain cells per 100 HT-29 cells, and Bifidobacterium bifidum, B. infantis and B. lactis ATCC strains were used as controls.
[0102] As a result, it was confirmed that the intestinal adhesion of the CJRS-10671 strain was 217±21 bacteria / 100 cells, which was equivalent to or higher than that of the control strain ( Figure 3 ).
[0103] Example 7: Immunization by strains enhances cytokine secretion
[0104] 7-1. Secretion of interleukin (IL)-6 in macrophage cell lines
[0105] It was determined whether the secretion of IL-6, a known immune-enhancing cytokine, was induced in immune cells by CJRS-10671 and CJRS-10672 of Example 1. Mouse macrophage cell line (Raw 264.7) and human monocytes (THP-1) were used as immune cells. One week before the experiment, the Raw 264.7 cell line was subcultured and maintained in DMEM containing 10% FB and 1% antibiotic-antimycotic, and 6×10 cells were plated in a flat 96-well plate one day before the experiment. 4 THP-1 cells were subcultured and maintained in RPMI medium containing 10% FBS, 1% penicillin-streptomycin (PS) and 0.05 mM 2-mercaptoethanol (2-ME) and plated at 8 × 10 cells / well in 96-well plates two days before the experiment. 4The cells / wells were inoculated, and then treated with 25ng / mL phorbol 12-myristate 13-acetate (PMA) to induce human monocytes to differentiate into human macrophages for two days. Then, when co-culturing cells with CJRS-10671 and CJRS-10672, an antibiotic-free culture medium containing 10% FBS was used as culture medium. After cultivation, the total cell count of CJRS-10671 and CJRS-10672 was measured and calculated with Novocyte instruments, and then treated with immune cells in a ratio of 1:10. After co-culturing for 24 hours, the cultured plates were centrifuged to precipitate cells and obtain only supernatant, which was then used to detect the secretion of cytokines. The analysis samples were prepared using BD Cytometric Bead Array (CBA) mice / human flex (flex) groups from BD Biosciences, and read by BD Lyric (flow cytometer), and the results were analyzed with FCAP software.
[0106] As a result, it was confirmed that CJRS-10671 and CJRS-10672 increased the secretion of IL-6 when co-cultured with mouse or human macrophages ( Figure 4 ).
[0107] 7-2. Secretion of IL-12p70 in human peripheral blood mononuclear cells (PBMC)
[0108] We determined whether CJRS-10671 and CJRS-10672 induce secretion of IL-12p70, a known immune-enhancing cytokine, in human PBMCs. 5 Human PBMCs were inoculated at 10 cells / well. Then, when co-culturing cells with CJRS-10671 and CJRS-10672, an antibiotic-free medium containing 10% FBS was used as a culture medium. After culture, the total cell counts of CJRS-10671 and CJRS-10672 were measured and calculated using a Novocyte instrument, and then treated with immune cells at a ratio of 1:10. The supernatant was obtained after 24 hours of culture, and as a result of the analysis, it was confirmed that CJRS-10671 and CJRS-10672 increased the secretion of IL-12p70 when co-cultured with human PBMCs ( Figure 5 ).
[0109] 7-3. Interferon-γ secretion by CD8 T cells in mouse splenocytes and human PBMCs
[0110] It is known that the IFNγ secretion capacity of CD8 T cells, cytotoxic T cells, has a great influence on anticancer efficacy. To determine the IFNγ secretion capacity of cytotoxic T cells by CJRS-10671 and CJRS-10672 strains, CD8 was detected using mouse spleen cells and human PBMCs. + IFNγ + .
[0111] Specifically, in order to separate mouse splenocytes, Hanks balanced salt solution (HBSS) containing collagenase IV is inserted into mouse spleen tissue by using a syringe that allows cells to flow out. After repeating this procedure many times, the remaining tissue is cut into small pieces by using a syringe and incubated at 37°C for 25 minutes. After adding 0.5M EDTA, incubate at 37°C for 5 minutes. Stir the cells with a Pasteur pipette and then filter the cells by a cell culture machine. After centrifugation at 1,500rpm for 3 minutes, remove red blood cells with 1×RBC lysis buffer, and suspend the splenocytes in fresh culture medium and use for experiments.
[0112] Human PBMCs were purchased from STEMCELL Technologies and stored in a nitrogen tank upon receipt before use in the experiment. On the day of the experiment, the stock was taken out of the nitrogen tank and thawed in a constant temperature water bath. RPMI 1640 supplemented with 10% FBS was added thereto, followed by centrifugation at 1,500 rpm for 5 minutes, and then the PBMCs were resuspended in fresh culture medium and used in the experiment.
[0113] T cell stimulators were required to determine the IFNγ secretion capacity of mouse splenocytes, therefore, one day before co-culture with the strain, 0.1 μg / mL anti-CD3 antibody diluted in PBS was coated in a flat 96-well plate at a concentration of 0.1 μg / mL in a volume of 100 μL per well. On the day of co-culture, after washing twice with PBS, the coated plates were prepared, mouse splenocytes were isolated according to the protocol, and then coated in a 96-well plate containing 1 μg / mL purified anti-CD28 antibody at a concentration of 5×10 5 Cells / well were inoculated. CJRS-10671 and CJRS-10672 strains were co-cultured with spleen cells at a ratio of 1:10 using antibiotic-free medium. After three days of co-culture, brefeldin A was added, followed by Golgi-stop for 3 to 4 hours, and then markers and fluorescent antibodies to be examined with the BD transcription factor buffer set were stained to prepare analysis samples. The analysis samples were analyzed using BD Cyric (flow cytometer) and Flowjo software, and the results were evaluated.
[0114] 2×10 5 Human PBMCs were seeded at 10 cells / well and co-cultured by the same method as in Example 7-2.
[0115] As a result, it was confirmed that CJRS-10671 and CJRS-10672 increased the IFNγ secretion capacity of CD8 T cells in mouse splenocytes and human PBMCs ( Figure 6 ).
[0116] Example 8: Cell cycle regulation of cancer cells by strains
[0117] 8-1. Cell cycle arrest in cancer cells
[0118] The cell cycle regulation of cancer cell lines by the CJRS-10671 and CJRS-10672 strains of Example 1 was examined. Lung cancer cell line Lewis lung cancer LL / 2 (LLC1) and colorectal cancer cell line mouse carcinoma-38 (MC38) cells were used as cancer cell lines. One week before the experiment, LLC1 and MC38 cell lines were cultured and maintained in DMEM containing 10% FBS and 1% antibiotic-antimycotic (Anti-anti). LLC1 and MC38 cell lines were each incubated at 2.4×10 5 cells / well and 1.2×10 5 Cells / well were seeded in 6-well plates. In order to synchronize the cell cycle to the G0 / G1 phase, the plates were washed twice with 1×PBS after 24 hours, and then the culture medium was exchanged with an antibiotic-free culture medium containing 0.5% FBS. CJRS-10671 and CJRS-10672 strains were added so that the ratio of cancer cell line: strain was 1:10, 1:100 or 1:1000. After 24 hours of co-culture, the cells were separated with trypsin-EDTA and washed with 1×PBS, and then 5 mL of ice-cold 75% EtOH was added while only the cells were left, and then stored at -20°C overnight. Subsequently, Ki67 and PI fluorescence staining were performed, and the cell cycle results were analyzed using BD Lyric (flow cytometer) and Flowjo software. The group not treated with CJRS-10671 and CJRS-10672 strains (strain-untreated group) was used as a control group.
[0119] As a result, it was confirmed that the cell cycle arrest effect was observed in the strain-treated group compared with the strain-untreated group, and that the cell cycle arrest effect was mainly induced by JRS-10671 in the G2 / M phase ( Figure 7 ).
[0120] 8-2. Expression of cyclin B1, cyclin-dependent kinase 1 (CDK1), and cancer cell cycle arrest-related factors
[0121] The changes in the expression of cyclin B1 and CDK1, which are G2 / M cell cycle regulation-related factors in cancer cell lines, caused by CJRS-10671 and CJRS-10672 strains were detected. LLC1 cells were co-cultured with CJRS-10671 and CJRS-10672 strains for 24 hours by the same method as in Example 8-1, and RNA was then extracted from the cells using TRIzol. cDNA was synthesized therefrom, and PCR was performed using QuantStudio 5 real-time PCR system to measure relative expression levels. The group (strain-untreated group) not treated with CJRS-10671 and CJRS-10672 strains was used as a control group.
[0122] As a result, it was confirmed that cyclin B1 and CDK1 associated with G2 / M cell cycle arrest were decreased, and the relative expression levels of cyclin B1 and CDK1 in LLC1 were mainly decreased in the group treated with the strain compared with the strain-untreated group ( Figure 8 ).
[0123] Example 9: Cancer cell death caused by bacterial strains
[0124] In order to determine the changes in the survival rate of cancer cell lines caused by the CJRS-10671 and CJRS-10672 strains of Example 1, LLC1 and MC38 cells were cultured at 2.4×10 5 cells / well and 1.2×10 5 Cells / well were seeded in 6-well plates. After 24 hours, the culture medium was exchanged with a culture medium containing 0.5% FBS, and serum starvation was continued for 24 hours. CJRS-10671 and CJRS-10672 strains were used for treatment, so that the ratio of cancer cell line: strain was 1:10, 1:100 or 1:1000. After 24 hours of co-culture, the cells were separated with trypsin-EDTA and washed with 1×PBS, and fluorescently stained with Fixable Viability Stain 510 antibody to distinguish dead cells from live cells, and cell survival results were analyzed using BD Lyric (flow cytometer) and Flowjo software. The total cell number was calculated as 100%, and the ratio of live cells to dead cells is shown in the accompanying drawings.
[0125] As a result, it was confirmed that the cell survival rate in the group treated with the strain was decreased compared with the strain-untreated group ( Fig. 9 ).
[0126] Example 10: Anticancer effect of strains in mouse lung cancer (LLC1) model
[0127] 10-1. Tumor inhibitory effect
[0128] To construct an animal model of lung cancer, LLC1 cells were cultured at 4 × 10 5 cells / mouse were injected subcutaneously into c57BL / 6 mice. When the tumor size reached approximately 30-50 mm after tumor cell injection 3 At the time of injection, the mice were divided into the following groups: negative control group (no treatment after tumor cell injection), CJRS-10671 or CJRS-10672 sample treatment group, immune checkpoint inhibitor anti-PD-1 treatment group (positive control group), and CJRS-10671 or CJRS-10672 sample and anti-PD-1 co-treatment group. CJRS-10671 or CJRS-10672 samples were diluted to 10 per animal in 100 μL PBS. 9 CFU and administered 10 times in 10 days, and anti-PD-1 (10 mg / kg, BioXCell) was administered intraperitoneally once every two days. Tumor size was measured 3 times a week with a caliper, and the next day after the end of administration, the mice were sacrificed to measure the weight of the tumor and analyze blood and organs.
[0129] The results confirmed that CJRS-10671 reduced tumor size even by single administration, and showed excellent tumor inhibitory effect when co-administered with anti-PD-1, compared with the anti-PD-1 single administration group. CJRS-10672 showed a slight effect by single administration, but showed a significantly excellent tumor inhibitory effect when co-administered with anti-PD-1 ( Fig.10 ).
[0130] 10-2. IFNγ secretion ability of CD8 T cells
[0131] After the test in Example 10-1 was completed, spleen cells were separated from spleen tissues of each group and then 6 Cells / well were seeded in a round-bottom 96-well plate. Splenocytes were stimulated with PMA / Ionomycin, which stimulates all immune cells, for 3-4 hours, followed by surface marker staining and intracellular cytokine staining (ICS). Subsequently, the amount of IFNγ secreted by CD8 T cells was determined by FACS. In order to further determine the efficacy of CD8 T cells, the same isolated splenocytes were stimulated with CD3 / CD28 (2 μg / mL anti-CD3 antibody and 2 μg / mL anti-CD28 antibody) to stimulate T cells for one day, followed by surface marker staining and ICS. Subsequently, the amount of IFNγ secreted by CD8 T cells was determined by FACS.
[0132] As a result, in the CJRS-10671 and anti-PD-1 co-administration group, it was confirmed that the amount of IFNγ secreted by CD8 T cells increased significantly after stimulation of all immune cells, and the amount of IFN-γ secreted by CD8 T cells tended to increase after stimulation of T cells ( Fig.11 In the CJRS-10672 and anti-PD-1 co-administration group, the amount of IFNγ secreted by CD8 T cells after stimulation of all immune cells was similar to that of the anti-PD-1 alone administration group, while the amount of IFN-γ secreted by CD8 T cells increased significantly after stimulation of T cells ( Fig.12 ).
[0133] 10-3. IFNγ secretion capacity of CD8 T cells in cancer tissues
[0134] After the test of Example 10-1 was completed, tumor infiltrating lymphocytes (TIL) were isolated from the tumor tissues of each group, and then stimulated with CD3 / CD28 (2 μg / mL anti-CD3 antibody and 2 μg / mL anti-CD28 antibody) to stimulate T cells for one day, and then surface marker staining and ICS were performed. Subsequently, the amount of IFNγ secreted by CD8 T cells was determined by FACS.
[0135] As a result, in the CJRS-10671 and anti-PD-1 co-administration group and the CJRS-10672 and anti-PD-1 co-administration group, the amount of IFNγ secreted by CD8 T cells after T stimulation cells increased ( Fig.13 ).
[0136] 10-4. Changes in immunosuppressive cells
[0137] After the test in Example 10-1 was completed, the CD11b + Gr-1 + Fluorescent staining of markers and FACS determined changes in myeloid-derived suppressor cells (MDSCs), known as immunosuppressive cells, in splenocytes and tumor cells of each group.
[0138] As a result, MDSCs in splenocytes increased in the negative control group, but decreased in the CJRS-10671 and anti-PD-1 co-administration group and the CJRS-10672 and anti-PD-1 co-administration group. In addition, it was confirmed that when the same markers were used in the tumor, MDSCs were significantly reduced in the CJRS-10671 and anti-PD-1 co-administration group and the CJRS-10672 and anti-PD-1 co-administration group compared with the negative control group ( Fig.14 ).
[0139] 10-5. Analysis of immune cell changes (profiling)
[0140] After the test in Example 10-1 was completed, spleen cells were isolated from spleen tissues of each group, and then surface markers were stained with fluorescent antibodies to determine the changes in immune cells and immunosuppressive cells. Fluorescent markers for each type of immune cell were used, as follows: M1 (CD11b + F4 / 80 + CD86 + )、M2(CD11b + F4 / 80 + CD206 + )、DC(IA-IE + CD11b + CD11c + ), B cells (CD3-B220 + ), NK cells (CD3-NK1.1 + ), NKT cells (CD3 + NK1.1 + ) and Treg (CD4 + CD25 + Foxp3 + ). The analytical samples were analyzed using BD Lyric (flow cytometer) and Flowjo software, and the results were then evaluated as % and #.
[0141] As a result, in the groups of CJRS-10671 and CJRS-10672 alone or in combination with anti-PD-1, the % and # values of M1, DC, and NKT cells tended to increase ( Fig.15 and Fig.16 ).
[0142] The CJRS-10671 and CJRS-10672 strains were deposited at the Korea Microorganism Conservation Center, a depository institution under the Budapest Treaty, on October 19, 2021, and were given the accession numbers KCCM13059 and KCCM13060P, respectively.
[0143] Therefore, without departing from the technical spirit or its essential characteristics, those skilled in the art to which the present disclosure belongs will be able to understand that the present disclosure may be embodied in other specific forms. Therefore, the above embodiments should be interpreted as illustrative rather than limiting the present disclosure. It should be understood that all changes or modifications derived from the definition and scope of the claims and their equivalents fall within the scope of the present disclosure.
[0144]
[0145]
Claims
1. Leuconostoc mesenteroides strain CJRS-10671 (Accession No.: KCCM13059P).
2. Leuconostoc mesenteroides CJRS-10672 (Accession No.: KCCM13060P) strain.
